Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 573.5 DKK 1.06% Market Closed
Market Cap: 40.7B DKK

Relative Value

The Relative Value of one ZEAL stock under the Base Case scenario is 163.8 DKK. Compared to the current market price of 573.5 DKK, Zealand Pharma A/S is Overvalued by 71%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZEAL Relative Value
Base Case
163.8 DKK
Overvaluation 71%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
6
vs Industry
12
Median 3Y
101.4
Median 5Y
74.1
Industry
7.3
Forward
34.9
vs History
vs Industry
Median 3Y
-15
Median 5Y
-12.9
Industry
21.6
Forward
-33
vs History
vs Industry
Median 3Y
-19.5
Median 5Y
-14.2
Industry
19.8
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-11.4
Industry
24.9
vs History
82
vs Industry
4
Median 3Y
9.6
Median 5Y
6.9
Industry
2.4
vs History
6
vs Industry
10
Median 3Y
95
Median 5Y
73.2
Industry
7.4
Forward
28.2
vs History
8
vs Industry
7
Median 3Y
80.1
Median 5Y
58.8
Industry
9.3
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-13.4
Industry
3.9
Forward
74.5
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-12.7
Industry
3.7
Forward
-24.4
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-12.2
Industry
4.9
vs History
vs Industry
Median 3Y
-17.2
Median 5Y
-11.4
Industry
3.2
vs History
45
vs Industry
0
Median 3Y
52.2
Median 5Y
31.6
Industry
4.3

Multiples Across Competitors

ZEAL Competitors Multiples
Zealand Pharma A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
40.5B DKK 646.3 -37.6 -26.3 -25.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 547 712.8 -173 705.9 -210 934.3 -208 527.2
US
Abbvie Inc
NYSE:ABBV
374.2B USD 6.6 88.3 17.2 26
US
Amgen Inc
NASDAQ:AMGN
169.1B USD 5.1 41.4 16.6 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
131.9B USD 4.6 274.8 10.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
131.1B USD 11.9 -244.7 26.8 28.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 927.6 -491.9 -535.6 -521.3
AU
CSL Ltd
ASX:CSL
122.7B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.6B USD 5.1 16.5 10.8 12.1
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.2 -55.3
NL
argenx SE
XBRU:ARGX
34B EUR 16.8 44.3 327.6 -2 413.4
P/S Multiple
Revenue Growth P/S to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/S: 3 322 760
646.3
205%
3.2
FR
Pharnext SCA
OTC:PNEXF
36 547 712.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.9
10%
1.2
US
E
Epizyme Inc
F:EPE
1 927.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 82.2
Negative Multiple: -37.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 705.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.4
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
274.8
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
44.3
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 61
Negative Multiple: -26.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 934.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
327.6
168%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 21.8
Negative Multiple: -25.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 413.4 N/A N/A